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ABSTRACT 
        Nonalcoholic steatohepatitis (NASH) is a highly prevalent liver disease in the world. 
About 15% to 25% of patients with NASH may progress to cirrhosis and hepatocellular  
carcinoma. However, there remains no U.S. Food and Drug Administration (FDA)-approved 
therapy for NASH. Our previous studies indicate that the combination of leucine and metformin 
or leucine and icariin, a phosphodiesterase type 5 inhibitor (PDE5i), improved nonalcoholic fatty 
liver disease (NAFLD) in Diet-induced Obesity (DIO) mice. Here we aim to evaluate the syner-
gistic effect of leucine, metformin and sildenafil combination (Leu-Met-Sil) on NASH in Ather-
osclerosis diet-induced mouse model. Our data show that the Leu-Met-Sil combination signifi-
cantly suppressed hepatic steatosis and fibrosis. This was associated with reduced alanine ami-
notransferase (ALT) levels in circulation. The Leu-Met-Sil combination also decreased inflam-
mation and increased fatty acid oxidation in liver, which may contribute to the beneficial effects 
of the treatment on the NASH phenotype. We conclude that Leu-Met-Sil combination could be a 
novel therapy for the treatment of NASH. 
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1. INTRODUCTION 
        Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) are 
highly prevalent liver diseases. Approximately 25% of the American adult population currently 
has NAFLD. Furthermore, 20-30% of NAFLD patients will develop into NASH that may pro-
gress to cirrhosis, end-stage liver disease, and hepatocellular carcinoma 1 2. Patients with NASH 
have an increased risk of complications after surgery, but such abnormal data had been ignored 
for a long time. Recently, NAFLD was found to be a cause of primary dysfunction after liver 
transplantation. To date, livers with severe steatosis (more than 60% of liver cells with hepato-
cyte ballooning) are universally rejected for liver transplantation, and there are concerns about 
survival rate after transplantation with moderate steatosis (30% to 60% of hepatocytes with fat 
droplets). 
The prevalence of NASH as a cause of severe liver disease is expected to increase in the 
western countries in the future. Fatty liver is commonly found in patients with type 2 diabetes 
and obesity, and a great concern for the world is the rapidly growing prevalence of these diseases 
in the United States and Europe countries. Recent surveys suggest that people with type 2 diabe-
tes will increase dramatically in the next century. It is estimated that 29 million people will be 
diagnosed with type 2 diabetes by 2050 in United States3. About 50% of the increase can be at-
tributed to the increasing age of the population, and more extensive obesity in demographic 
composition account for the other half. Obesity is also increasing as a worldwide epidemical 
problems even in developing countries4. Based on this information, it is expected that an even 
larger population will be at risk of developing NASH in the near future. 
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Current approaches to NASH treatment have been largely unsuccessful and primarily focus on 
the lifestyle change. There is no U.S. Food and Drug Administration (FDA)-approved therapy 
for NASH 5. Thus, our study aims to find a novel pharmacological treatment for NASH. 
SIRT1 and Adenosine Monophosphate (AMP)-Activated Protein Kinase (AMPK) regu-
late energy metabolism through sensing Nicotinamide Adenine Dinucleotide (NAD+) and AMP 
levels6-9, respectively. Due to their mutual activation, AMPK and SIRT1 are activated by com-
mon activators, and produce overlapping outcomes through stimulating peroxisome proliferator-
activated receptor γ co-activator α (PGC1 α) to regulate mitochondrial biogenesis and energy 
expenditure.10, 11 The SIRT1–AMPK axis is suppressed in replete energy states such as obesity 
and diabetes. Activation of this axis improves insulin resistance, and lipid metabolism.12-14 
Branched-chain amino acid L-leucine activates SIRT115-18 , which subsequently activates 
AMPK through SIRT1–AMPK axis 13, 14, 15 . This results in significant synergy of leucine with 
polyphenols, a SIRT 1 activator, and with metformin, leading to significant increases in efficacy 
of treatment. 15-19 
Nitric oxide (NO) levels also response to energy status and are increased during caloric 
restriction. Increased NO stimulates SIRT1 activity20, 21. SIRT1 reciprocally increases NO levels 
via deacetylation (Lys 496; Lys 506) of endothelial nitric oxide synthase (eNOS)22, 23. AMPK 
plays a similar role via phosphorylating eNOS (Ser 1177)24, 25. Thus, SIRT1, AMPK, and NO 
form a cross-talk energy-sensing network. The classically-established NO action mode is stimu-
lating soluble NO-sensitive guanylyl cyclase (GC) to  increase cGMP, and initiating subsequent 
physiological changes primarily via cGMP-dependent protein kinases (PKGs)26. cGMP signaling 
termination depends on dependent upon phosphodiesterase (PDE)-mediated hydrolysis. Compa-
rable effects are obtained by inhibiting cGMP-specific PDE5 using specific inhibitors, such as 
3 
sildenafil and icariin26, 27. However, these PDE5i also activate eNOS28-30 and may increase 
SIRT1 activity and improve lipid metabolism and insulin signaling.28,31, 32 
Our published data indicate that L-leucine and PDE5i combination not only promoted in-
sulin sensitivity but also improved NAFLD in Diet-induced Obesity (DIO) mice33. 
Metformin is considered as the first-line drug for treating type 2 diabetes. It exhibits an 
excellent safety profile and does not promote weight gain34 However, its therapeutic function is 
often limited by dose-related gastrointestinal adverse effects (especially at the full therapeutic 
dose of 1500 to 2000 mg/day). This leads to dose reduction and/or compliance issues in 30% of 
patients and drug discontinuation in up to 10% of patients35. Moreover, metformin monotherapy 
often fails to achieve optimal glycemic control due to inter-individual variability in response to 
drug initiation and maintenance.36 
Metformin lowers blood glucose mainly through suppressing hepatic glucose production 
and increasing peripheral glucose disposal37-39. Most of these effects depend on AMPK/Sirt1 
pathway activation. Metformin inhibits mitochondrial respiratory chain complex 140and AMP-
deaminase 41. These result in elevated AMPK activity. AMPK activation increases 
NAD+/NADH ratio, which leads to increased SIRT1 activity42. 
Type 2 diabetes is characterized by insulin resistance, which leads to impaired glucose 
and lipid metabolism in muscle, adipose tissue, and liver. AMPK and Sirt1 are two key regula-
tors of energy status.  They are bidirectional and cross-activated, and they produce similar meta-
bolic effects43, 44. Decreased activity of the AMPK/Sirt1 axis is associated with obesity, insulin 
resistance, and diabetes. However, activating either one prevents and improves hyperglycemia 
and insulin resistance.12-14, 45 
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Our previous studies indicate that the combination of leucine with a low dose of metfor-
min not only promoted insulin sensitivity but also improved NAFLD in Diet-induced Obesity 
(DIO) mice19. Similarly, we found that leucine and PDE5 inhibitor combination had the same 
effect on NAFLD33. The present study was designed to more comprehensively evaluate the effi-
cacy of synergistic effect of leucine-metformin-PDE5i (sildenafil) on NASH (Figure 1).   
 
    
Figure 1  Overall hypothesis.  
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2    MATERIALS AND METHODS 
2.1. Animal Model 
        Eighty 6-week old male C57BL/6 mice from Jackson Lab were put on either low-fat (LF) 
diet or HF/ATH (atherogenesis)(containing 1.25% cholesterol, 0.5% cholate by weight and 60% 
calories as saturated fat (lard) ) for 4 weeks to induce NASH. Based on the ALT levels measured 
in serum of NASH model, mice were then be assigned to receive either the LF or the HF/ATH 
diet with or without different leucine-metformin-sildenafil (Leu-Met-Sil) combinations indicated 
in the table (Table.1) for an additional 5 weeks 
        Animals were housed in polypropylene cages at room temperature of 22o C with a 12 h 
light/dark cycle. The animals had free access to water and assigned food throughout the experi-
ment. Body weight was measured weekly. After 5-week treatment, all of the animals were eu-
thanized with CO2 and dissected. Blood and tissues were collected for further experiments. This 
study and all animal procedures were conducted under the auspices of an Institutional Animal 
Care and Use Committee-approved protocol of the Georgia State University. 
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Table 1 The Composition of Diets 
 
Table 1. The Composition of Diets 
Composition 
LF 
(LF) 
HF/ATH 
(HC) 
HF/ATH+Sil 
(Sil) 
HF/ATH+Leu+Sil 
(Leu-sil) 
HF/ATH 
Leu+Met 
(Leu-Met) 
HF/ATH+Sil+Met 
(Met-Sil) 
HF/ATH+Leu+Met+Sil 
(Leu-Met-Sil) 
Calories from 
fat 10% 60% 60% 60% 60% 60% 60% 
Cholesterol N. 1.25% 1.25% 1.25% 1.25% 1.25% 1.25% 
Cholate N. 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 
Leu N. N. N. 24 g/kg diet 24 g/kg diet N. 24 g/kg diet 
Met N. N. N. N. 0.25 g/kg diet 0.25 g/kg diet 0.25 g/kg diet 
Sil N. N. 
25mg/kg 
diet 25mg/kg diet N. 25mg/kg diet 25mg/kg diet 
Abbreviations: LF, Regular chow diet; HF/ATH, High fat/atherogenic diet; Leu, L-Leucine; Met, Metformin; Sil, Sildenafil; 
 
 
2.2.Serum Biochemistry 
        Blood was collected via tail vein, and Total Cholesterol (TC) and Triglyceride (TG) were 
measured using Kit from Wako Pure Chemical Industries (Osaka, Japan). Serum C-reactive pro-
tein (CRP) levels were measured in fed mice using a mouse CRP enzyme linked immunosorbent 
assay kit (ELISA) (Life Diagnostics, West Chester, PA, USA). Serum ALT levels were meas-
ured in fed mice using a mouse ALT ELISA kit from BioVision. 
2.3.Quantitative Real-Time PCR 
Total RNA from liver was extracted using the Tri-Reagent kit (Molecular Research Cen-
ter, Cincinnati, OH, USA), and gene expression was assessed by quantitative reverse transcrip-
tion-polymerase chain reaction (PCR) (ABI Universal PCR Master Mix; Thermo Fisher Scien-
tific, Waltham, MA, USA) using a Stratagene Mx3000P thermocycler  (Stratagene, La Jolla, CA, 
USA). The gene expression data were normalized to the house keeping gene 18s. The primer and 
probe sets used in the assays were purchased from Thermo Fisher Scientific (Waltham, MA, 
USA) and are further described in Table 2. 
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Table 2  RT-PCR probes ID and sequences 
 
2.4.Tissue Preparation and Historical Examination 
Liver tissues were fixed in 10% neutral formalin, embedded in paraffin, and cut into 5 
µm sections. Sections were processed for hematoxylin and eosin staining. For inflammation im-
munostaining, slides were immunoblotted with CD68 (Bio-Rad MCA 1957) as primary antibody 
and Biotin-SP-AffiniPure Mouse Anti-Rat IgG as secondary antibody. This was followed by the 
application of the immunoperoxidase technique with a Vector kit. Areas of staining were quanti-
fied with ImageJ and expressed as percentages of the field area. For fibrosis Picro-Sirius Red 
staining, liver slides were dewaxed and hydrated. Weigert's hematoxylin stained for 8 mins and 
Picro-Sirius Red (Picro Sirius Red Stain Kit, abcam150681) stained for one hour. Acidified wa-
ter wash was applied. Slides were dehydrated in three changes of 100% ethanol and Clear in xy-
Table 2. RT-PCR probes ID and sequences 
 
ABI assay ID 
  TGFβ1 Mm01178820_m1 
  Coll1α1 Mm00801666_g1 
  Coll1α2 Mm00483888_m1 
  Coll4α1 Mm01210125_m1 
  PAI-1 Mm00435860_m1 
  IL-6 Mm00446190_m1 
  IL-1β Mm01336189_m1 
  TNFα Mm00443258_m1 
  MCP1 
(ccl2) Mm00441242_m1 
  FAS Mm01204974_m1 
  SCD1 Mm00772290_m1 
  
 
Forward Reverse Probe 
18S AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC CGCCCGTCGCTACTACCGATTGG 
PPAR α GACAAGGCCTCAGGGTACCA GCCGAATAGTTCGCCGAAA AGCCCTTACAGCCTTCACATGCGTGA 
Abbreviations: ABI, Applied Biosystems Inc (Foster City, CA , USA); RT-PCR , reverse transcription polymerase chain reac-
tion; FAS, fatty acid synthase; SCD1, stearoyl-CoA desaturase-1; COX1, cyclooxygenase 1; AC OX1, acyl-CoA oxidase; CPT1A, 
carnitine palmitoyltransferase 1A; CPT1B, carnitine palmitoyltransferase 1B; IL -6, interleukin 6; IL -1β, interleukin-1 beta; 
TNFα, tumor necrosis factor alpha; MCP1, monocyte chemotactic protein 1; ACC , acetyl CoA carboxylase; PPAR α, peroxi-
some proliferator-activated receptor alpha. 
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lene and mounted in a resinous medium. All of the histological images were recorded using Ni-
kon Eclipse E800 Microscopy with Zeiss AxioCam camera in Image Core facility of Georgia 
State University. 
2.5.Hepatic Lipid Analysis 
Liver lipid extraction was conducted as previously described by Bligh and Dyer with mi-
nor modifications 46. Briefly, ~100mg of liver was thawed, minced and weighted in glass tube. 
Add 3ml CHCl3:MeOH (2:1) to extract lipid at room temperature overnight. Transfer lipid ex-
traction into new glass tube, wash liver tissue with CHCl3:MeOH (2:1) twice and dry down the 
combined solvent at 60°C. Add 3ml CHCl3:MeOH (2:1) and 0.6ml 0.05% H2SO4 into tube, and 
split the phase by 2000rpm centrifugation for 15 minutes. An aliquot of the bottom phase was 
dried down and the lipid extraction was dissolved in 2% Triton X-100.  Triglyceride (TG) was 
measured using TC, TG kit (Wako Chemicals, USA) with liver weight correction. 
2.6.Western Blot 
The P-AMPK and AMPK antibodies were obtained from Cell Signaling (Danvers, MA). 
GAPDH antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Protein levels 
of cell extracts were measured by BCA kit (Thermo Scientific).  For Western blot, 10-50 μg pro-
tein was resolved on 4-15% gradient polyacrylamide gels (Criterion precast gel, Bio-Rad La-
boratories, Hercules, CA), transferred to either PVDF or nitrocellulose membranes, incubated in 
blocking buffer (3% BSA or 5% non-fat dry milk in TBS) and then incubated with primary anti-
body (1:500 dilution), washed and incubated with horseradish peroxidase- or fluorescence-
conjugated secondary antibody (1:5000 dilution). Total ACC was detected using Streptavidin-
conjugated horseradish peroxidase (Amersham Biosciences, Piscataway, NJ). Visualization was 
conducted using BioRad ChemiDoc instrumentation and software (Bio-Rad Laboratories, Hercu-
9 
les, CA) or Li-COR Odyssey Fc Imaging system (Li-COR Biosciences) and band intensity was 
assessed using Image Lab 4.0 or Quantity One (Bio-Rad Laboratories, Hercules, CA), with cor-
rection for background and loading controls 
2.7.Statistical Analysis 
All data are expressed as mean ± SEM.  Data were analyzed by one-way ANOVA, and 
significantly different group means (p< 0.05) were separated by the least significant difference 
test using GraphPad Prism version 6 (GraphPad Software, La Jolla California USA, 
www.graphpad.com). 
 
3. RESULTS 
3.1.Leu-Met-Sil combination did not change body weight but decreased liver weight. 
 
Figure 2  Leu-Met-Sil combination did not change body weight but decreased liver 
weight 
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        To date, NASH studies have been impeded by the absence of a suitable experimental model. 
Genetic targeted defects23 and overexpression24 rats have been used in NAFLD model. However, 
genetic manipulations cannot reflect the natural etiology of NAFLD in clinical studies and rarely 
lead to the pathology of NASH. The alternative option is nutritional manipulation models. Su-
crose-rich and fat-rich diet25 just accumulate minimal fat and develop subtle inflammation in liv-
er. The methionine and choline-deficient model (MCD)26, 27 is frequently used to produce more 
progressive liver pathology. However, this model has no insulin resistance 28. In this study, we 
mainly focus on an atherogenic (Ath) diet, which contains cholesterol and cholic acid. This diet 
has been reported to induce liver steatosis, inflammation, and fibrosis29 
        To build the NASH mouse model, eighty 6-week old male C57BL/6 mice from Jackson Lab 
were put on either a low-fat (LF) diet or a HF/ATH (atherogenesis)(containing 1.25% cholester-
ol, 0.5% cholate by weight and 60% calories as saturated fat (lard) ) for 4 weeks to induce NASH 
(Figure 2-A). To assess the NASH development, blood was collected from tail vein. ELISA 
method was used to measure alanine aminotransferase (ALT) in serum to detect the liver damage 
levels. Based on the measured ALT levels, mice were then be assigned to receive either the LF 
or the HF/ATH diet with or without different Leu-Met-Sil combinations indicated below for an 
additional 5 weeks (Figure 2-A). 
Interventions: 
LF (10% calories from fat)  (LF group) 
HF/ATH (1.25% cholesterol, 0.5% cholate, 60% calories from fat)  (HC group) 
HF/ATH + leucine (24 g/kg diet) + metformin (0.25 g/kg diet) (HC+Leu+Met group) 
HF/ATH + Sildenafil (25mg/kg diet) (HC +Sil group) 
11 
HF/ATH + leucine (24 g/kg diet) + Sildenafil (25mg/kg diet) (HC+Leu+Sil group) 
HF/ATH + metformin (0.25 g/kg diet) + Sildenafil (25mg/kg diet) (HC+Met+Sil group) 
HF/ATH + leucine (24 g/kg diet) + metformin (0.25 g/kg diet) + Sildenafil (25mg/kg diet) 
(HC+Leu+Met+Sil group) 
        To evaluate the treatment effect, body weight was monitored weekly.  Our data (Figure 2-
A) indicate that there were no changes in body weight among different groups. At the end of the 
study, the mice were euthanized and liver tissue was dissected. Our data show that Leu-Met-Sil 
treatment decreased liver weight (normalized to body weight) (Figure 2. B). 
3.2.Leu-Met-Sil combination reduced ALT levels in serum.  
ALT is a liver damage marker, which synthesized by liver and released into circulation 
when liver is damaged. To study the treatment effects, ALT levels in the serum were measured 
during treatment. Our data (Figure 3.A,B) show that the Leu-Met-Sil combination decreased 
ALT levels in serum. 
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Figure 3 Leu-Met-Sil combination reduced ALT levels in serum.  
 
         
3.3.Leu-Met-Sil combination reduced liver steatosis and lipid accumulation. 
         To further evaluate the treatment of the Leu-Met-Sil combination on NASH, Hematoxylin 
and Eosin staining (H&E staining) was performed in liver tissue to evaluate liver steatosis status. 
Liver lipids were also extracted and measured. Our data (Figure 4.A,B) indicate that Leu-Met-
Sil combination decreased liver steatosis and lipid accumulation. 
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Figure 4 Leu-Met-Sil combination reduced liver steatosis. 
 
3.4.Leu-Met-Sil combination decreased liver fibrosis.  
To assess the effect of Leu-Met-Sil combination on fibrosis, genes involved in fobrosis 
(Procollagen type I alpha 1 (Col Ia1); procollagen type I alpha 2 (Col Ia2); procollagen type IV 
alpha 1 (Col 4a1); PAI-1, Plasminogen activator inhibitor 1 (PAI-1)) and Transforming growth 
factor β (TGF-β) expression of liver were measured using Quantitative polymerase chain reac-
14 
tion (Q-PCR). Our data (Figure. 5) show that Leu-Met-Sil combination reduced fibrogenesis 
gene expression. 
  
Figure 5  Leu-Met-Sil combination decreased liver fibrogenesis gene expression. 
 
        To more thoroughly evaluate the liver fibrosis, Picro-Sirius Red staining was performed to 
assess the collagen accumulation. Our results show that (Figure. 6) Leu-Met-Sil combination 
15 
significantly reduced liver fibrosis. 
 
Figure 6 Leu-Met-Sil combination reduced liver fibrosis.  
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3.5. Leu-Met-Sil combination decreased hepatic inflammation.  
         To test inflammatory status after Leu-Met-Sil treatment, mRNA was isolated from liver 
tissue. Pro-inflammatory makers (IL6, IL-β, TNFα, MCP-1) were measured by using Q-PCR. 
CRP levels in serum were measured using ELISA kit.  
        Our results indicate that Leu-Met-Sil combination reduced liver pro-inflammatory genes 
expression (Figure.7A-D) and serum C-reaction protein (CRP) levels(Figure.7E)        
 
Figure 7  Leu-Met-Sil combination decreased liver proinflammatory gene expres-
sion and serum CRP levels. 
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3.6. Leu-Met-Sil combination decreased liver macrophage infiltration. 
        To more thoroughly assess liver inflammatory levels, we performed CD68 immunostaining 
to detect macrophage infiltration. Our data indicate that Leu-Met-Sil combination decreased 
macrophage infiltration (Figure. 8), which further confirmed the anti-inflammatory effect of 
Leu-Met-Sil combination. 
 
Figure 8 Leu-Met-Sil combination decreased liver macrophage infiltration. 
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3.7. Leu-Met-Sil combination increased the expression of genes involved in fatty acid oxida-
tion in liver.  
       One of the hallmarks of NASH is lipid accumulation, which is due to dysregulation of fatty 
acid metabolism, including lipogenesis and fatty acid oxidation.  
        To examine the status of fatty acid synthesis and oxidation in the liver, we measured the 
expression of fatty acid synthase (FAS), stearoyl-CoA desaturase 1(SCD1) (Figure. 9A) and pe-
roxisome proliferator-activated receptor α (PPARα) (Figure. 9B).  
        Our data indicate that Leu-Met-Sil combination had a tendency to reduce the expression of 
SCD1 (p=0.06), while significantly upregulating the expression of PPARα. 
 
 
Figure 9.  Leu-Met-Sil combination increased the expression of genes involved in 
hepatic fatty acid oxidation. 
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3.8.Leu-Met-Sil combination did not change hepatic AMPK signaling.  
          To investigate whether AMPK mediates the beneficial effect of Leu-Met-Sil combination, 
we measured phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase 
(ACC). 
         Our data show that Leu-Met-Sil combination did not change AMPK signaling (Figure. 10), 
suggesting that Leu-Met-Sil did not function through AMPK pathway.  
 
Figure 10 Leu-Met-Sil combination did not change hepatic AMPK signaling. 
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4     DISCUSSION AND CONCLUSION 
In this study, our data indicate that leucine-metformin-PDE5i combination reduced serum 
ALT levels, improved steatosis and hepatic ballooning, deceased inflammation and fibrogenesis 
representative gene expression, and increased fatty acid oxidation.  
NASH is defined as the presence of hepatic steatosis and inflammation with hepatocyte 
injury (ballooning) with or without fibrosis. To date, there is no efficient management of patient 
with NASH. Many studies indicate that lifestyle modification may improve hepatic steatosis47. In 
addition, metformin, Thiazolidinediones(TZD) and vitamin E are also used for clinical trials for 
treating NASH. However, there are either no significant effect or no well-evaluated safety and 
efficacy in NASH patient. Thus, we investigated the synergistic effect of Leucine, Metformin 
and PDE5i on NASH.  
PDE5-inhibitors, including sildenafil and tadalafil, have been demonstrated to increase 
SIRT1 signaling in mice,30, 31 to increase energy expenditure in skeletal muscle cells,48 to im-
prove energy balance, and to increase insulin action in both diet-induced obese (DIO), insulin-
resistant mice and diabetic patients.32, 49  This may be, in part, due to stimulation of eNOS and 
NO signaling and subsequent NO-mediated SIRT1 activation.30, 32  Leucine activation of SIRT1 
results in downstream activation of AMPK, while metformin activation of AMPK leads to 
SIRT1 activation via phosphorylation of NAMPT to regenerate NAD+. Both AMPK and SIRT1, 
in turn, activate eNOS via phosphorylation and deacetylation, respectively. The increased NO, in 
turn, may stimulate SIRT1 activity, resulting in a three-component feed-forward loop. 
Inflammation often represents the “second hit” and potentiates the risk for progression 
from simple steatohepatosis to NASH and cirrhosis.50 Obesity is associated with a generalized 
chronic inflammatory state and pro-inflammatory cytokines such as TNF-α, IL-6 and C-reactive 
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protein (CRP) are elevated in obese patients. 51 Pro-inflammatory cytokines have been suggested 
by some as noninvasive biomarkers to distinguish hepatosteatosis from NASH; although the clin-
ical utility of these markers in predicting severity of NASH and fibrosis is unclear, most studies 
have shown a positive correlation with higher inflammatory marker levels in NASH52, 53. In this 
study, all of the inflammatory markers in liver (IL6, IL1 beta, TNF alpha and MCP-1) and in 
plasma (CRP) were significantly blunted by the Let-Met-Silt treatment combinations.         
The full therapeutic dose of metformin used in mouse is 300mg/Kg bodyweight (BW) 
and very low dose is 50mg/Kg BW54, 55.  In our study, the intervention dose of metformin is 0.25 
g/kg diet (equal to 250mg/Kg diet)19, which is 25mg/KG BW after converting. Our preliminary 
data show that this dose of metformin synergized with leucine (24g/Kg diet) had effects against 
NAFL.  The normal leucine dietary intake in diet for a mouse is 60-70 mg/day. However, this 
dose is sufficient to activate Sirt1 pathway.  To achieve this goal, extra leucine is usually admin-
istrated via water in mouse study and the dose is 1.5g/100ml (1.5%w/v)56, 57.  This increases total 
intake of leucine to 130 mg/day/mouse, which is sufficient to activate Sirt1 pathway57. In our 
experiment, we administrated leucine via diet with the dose of 24g/Kg diet, which is 2.4g/Kg 
BW after converting. This administration can activate Sirt1 activity and make synergy of Leu-
Met-Sil become possible.  
Now, the absence of experimental model hampered NASH study. Genetic manipulations 
can evaluate the specific gene importance. However, they might not directly reflect the etiology 
in human NAFLD and rarely lead us to know the NASH pathology. Nutritional manipulations 
induced either mild NASH such as sucrose-rich and fat-rich diet or more progressive liver dam-
age such as methionine and choline deficient (MCD) model. In this study, we use ATH diet in-
duced NASH, which is a more physiological model compared with the models above. No genetic 
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or nutrient deficiency is involved in this model. Cholesterol and cholate are the main ingredients 
in the diet. These components resulted in accumulated cholesterol in the liver and induced stea-
tosis by cholesterol-induced toxicity. However, this model has some limitations, because it is still 
controversial that whether cholesterol, TG, FFA contributes to the development of NASH. In ad-
dition, it is not a well-studied NASH model. The exact molecular mechanisms involved in this 
model are still unknown.  In our results, we just observed the phenotype changes before and after 
the combination. However, the real reason why Leu-Met-Sil combination has effects is still un-
known. In the future study, we might use a different NASH model to study the development of 
NASH.  
In this study, Leu-Met-Sil combination did not significantly change fatty acid synthesis 
representative genes. Furthermore, AMPK is not involved in synergistic effects of Leu-Met-Sil. 
Leu-Met-Sil combination increased PPAR-α expression and decreased liver inflammation levels, 
which is a good explanation of decreased fibrosis.  Other downstream pathways of PPAR-alpha 
might involve in the combination effect, such as fatty acid transport protein (FATP), fatty acid 
translocase (FAT). The synergistic effects of Leu-Met-Sil might converge on the PDE5 inhibitor 
pathway. They might enhance cGMP-dependent protein kinases (PKGs) activity and then de-
crease liver inflammation and fibrosis58-60.  
In summary, Leu-Met-Sil combination improves NASH in Ath-induced NASH model 
and may give us a potential therapy for NASH in the future.  
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